{"id":"sodium-glucose-cotransporter-2-inhibitor","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"5-10","effect":"Urinary tract infections"},{"rate":"5-10","effect":"Osmotic diuresis/polyuria"},{"rate":"<1","effect":"Diabetic ketoacidosis"},{"rate":"5-10","effect":"Volume depletion/hypotension"},{"rate":"<0.1","effect":"Fournier's gangrene"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is a transporter protein in the proximal tubule of the nephron responsible for reabsorbing filtered glucose back into the bloodstream. By inhibiting this transporter, SGLT2 inhibitors reduce blood glucose levels by promoting urinary glucose loss, independent of insulin secretion. This mechanism also produces osmotic diuresis and has cardioprotective and renoprotective effects beyond glucose lowering.","oneSentence":"SGLT2 inhibitors block the sodium-glucose cotransporter 2 in the kidney, preventing reabsorption of glucose and increasing urinary glucose excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:31.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"},{"name":"Type 1 diabetes (in combination with insulin)"}]},"trialDetails":[{"nctId":"NCT07022379","phase":"","title":"Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program","status":"COMPLETED","sponsor":"Satelia","startDate":"2021-01-01","conditions":"Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Reduced Ejection Fraction","enrollment":13660},{"nctId":"NCT07491042","phase":"NA","title":"Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.","status":"RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2026-04-01","conditions":"End Stage Chronic Renal Failure","enrollment":38},{"nctId":"NCT04128995","phase":"PHASE4","title":"Surgical or Medical Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-15","conditions":"Diabetes Mellitus, Type 2, Pediatric Obesity, Bariatric Surgery Candidate","enrollment":88},{"nctId":"NCT07482943","phase":"PHASE4","title":"The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-04","conditions":"Fontan, Heart Failure, Dapagliflozin","enrollment":30},{"nctId":"NCT07482020","phase":"PHASE2","title":"SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03-01","conditions":"Atrial Fibrillation (AF), Hypertension","enrollment":66},{"nctId":"NCT05013112","phase":"NA","title":"Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-01-01","conditions":"Kidney Transplantation, Metabolic Disorder, Metformin","enrollment":105},{"nctId":"NCT06905405","phase":"","title":"The Use of Advanced Imaging in HFpEF","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2025-08-05","conditions":"Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":40},{"nctId":"NCT07478575","phase":"","title":"Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2019-01-01","conditions":"Heart Failure, Anemia, Renal Insufficiency","enrollment":85},{"nctId":"NCT07472920","phase":"NA","title":"Empagliflozin Adjunctive Therapy in Bipolar Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-03-09","conditions":"Bipolar Disorder, Bipolar Depression, Insulin Resistance","enrollment":20},{"nctId":"NCT05309785","phase":"PHASE4","title":"Safety and Efficacy of Canagliflozin in Advanced CKD","status":"ACTIVE_NOT_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-11-24","conditions":"ESRD, CKD Stage 4, CKD Stage 5","enrollment":35},{"nctId":"NCT05986136","phase":"PHASE2, PHASE3","title":"Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2023-08-20","conditions":"Inflammatory Bowel Diseases","enrollment":50},{"nctId":"NCT03878706","phase":"","title":"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","status":"RECRUITING","sponsor":"University of Athens","startDate":"2017-11-03","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT05182658","phase":"PHASE3","title":"Empagliflozin in Hypertrophic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-06-01","conditions":"Hypertrophic Cardiomyopathy, Heart Failure","enrollment":250},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT07450417","phase":"","title":"Effect of Early Empagliflozin Initiation in Cardiogenic Shock.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-03-10","conditions":"Cardiogenic Shock","enrollment":418},{"nctId":"NCT03982381","phase":"PHASE4","title":"SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2019-09-05","conditions":"Type 2 Diabetes","enrollment":2067},{"nctId":"NCT07063316","phase":"","title":"SGLT2 Inhibitors and Renal Anemia in Japan: RWD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-07-23","conditions":"Chronic Kidney Disease","enrollment":15000},{"nctId":"NCT07441187","phase":"","title":"Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-20","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":300},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT06430684","phase":"EARLY_PHASE1","title":"Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2024-08-23","conditions":"Chronic Kidney Diseases, Pediatric Kidney Disease","enrollment":40},{"nctId":"NCT07421518","phase":"PHASE2","title":"Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2026-06","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":75},{"nctId":"NCT07417306","phase":"PHASE3","title":"A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2026-03-27","conditions":"Type 2 Diabetes","enrollment":912},{"nctId":"NCT06932081","phase":"","title":"Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-01-01","conditions":"Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle","enrollment":400},{"nctId":"NCT05944432","phase":"NA","title":"CGM Use in Adults With Type 2 Diabetes on Basal Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Diabetes Care","startDate":"2023-07-14","conditions":"Diabetes Mellitus, Type 2","enrollment":470},{"nctId":"NCT07405944","phase":"PHASE4","title":"Vericiguat and Reverse Remodeling Indices in Heart Failure","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-11-01","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure","enrollment":60},{"nctId":"NCT05139914","phase":"PHASE4","title":"Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-05-31","conditions":"Diabetes Mellitus, Type 2, Endothelial Dysfunction","enrollment":4},{"nctId":"NCT07323524","phase":"PHASE4","title":"Dapagliflozin in Active Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-01","conditions":"Lupus Nephritis (LN)","enrollment":33},{"nctId":"NCT05669742","phase":"PHASE3","title":"Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-05-25","conditions":"Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics","enrollment":40},{"nctId":"NCT07379788","phase":"","title":"ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling","status":"RECRUITING","sponsor":"Rehab Werida","startDate":"2025-12-25","conditions":"Heart Failure","enrollment":180},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT06221969","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-01-16","conditions":"Type 2 Diabetes","enrollment":1000},{"nctId":"NCT07360457","phase":"","title":"GLP1 Analogues and the Risk of Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2026-02-01","conditions":"Osteoarthritis","enrollment":390},{"nctId":"NCT06065540","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":2734},{"nctId":"NCT07214818","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2025-11-15","conditions":"Nephrotic Syndrome","enrollment":75},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT06149793","phase":"PHASE2, PHASE3","title":"SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2024-01-08","conditions":"Cystic Fibrosis-related Diabetes, Cystic Fibrosis","enrollment":8},{"nctId":"NCT07351643","phase":"PHASE4","title":"CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-02-25","conditions":"ACS (Acute Coronary Syndrome), SGLT2 Inhibitors","enrollment":110},{"nctId":"NCT07351864","phase":"PHASE4","title":"Finerenone Plus SGLT2 Inhibitors in Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-18","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT07348718","phase":"","title":"Rubix LS Diabetic Kidney Disease (DKD) Registry Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rubix LS","startDate":"2025-12-15","conditions":"Diabetic Kidney Disease (DKD)","enrollment":2000},{"nctId":"NCT07348484","phase":"","title":"Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2026-01","conditions":"Chronic Kidney Disease","enrollment":300},{"nctId":"NCT07342764","phase":"PHASE4","title":"Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2026-04","conditions":"Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":120},{"nctId":"NCT07332156","phase":"","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)","enrollment":21692},{"nctId":"NCT06887062","phase":"PHASE2","title":"Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-21","conditions":"Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis","enrollment":60},{"nctId":"NCT07334145","phase":"","title":"Effect of SGLT2 Inhibitors on Anemic CKD Patients","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-01-01","conditions":"Anemia in CKD Patients","enrollment":60},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT07338331","phase":"NA","title":"Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Galala University","startDate":"2023-04-04","conditions":"Diabete Type 2, Non Alcoholic Fatty Liver","enrollment":80},{"nctId":"NCT01512849","phase":"PHASE1","title":"A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01387737","phase":"PHASE3","title":"Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1299},{"nctId":"NCT01022112","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":383},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT01413204","phase":"PHASE3","title":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-07","conditions":"Type 2 Diabetes Mellitus","enrollment":272},{"nctId":"NCT07322237","phase":"PHASE4","title":"DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors","enrollment":400},{"nctId":"NCT06858436","phase":"PHASE4","title":"SGLT2 Inhibitor Utilization Re-perfusion Therapy","status":"NOT_YET_RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2026-01-23","conditions":"Acute Ischemic Stroke From Large Vessel Occlusion","enrollment":150},{"nctId":"NCT05313529","phase":"NA","title":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-08","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":396},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07311109","phase":"NA","title":"A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-15","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":150},{"nctId":"NCT07172971","phase":"PHASE1","title":"Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Larry W. Markham","startDate":"2026-02-01","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":10},{"nctId":"NCT06297603","phase":"PHASE3","title":"Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-03-15","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT06609356","phase":"EARLY_PHASE1","title":"Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-07-03","conditions":"Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes","enrollment":27},{"nctId":"NCT05991284","phase":"PHASE4","title":"Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2024-02-29","conditions":"Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation","enrollment":84},{"nctId":"NCT07294495","phase":"NA","title":"Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR","status":"NOT_YET_RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-07","conditions":"HCM - Hypertrophic Cardiomyopathy","enrollment":150},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT07174687","phase":"PHASE2","title":"SGLT2 Inhibitors in Geographic Atrophy","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-12-02","conditions":"Retinal Degeneration, Retinal Diseases, Eye Diseases","enrollment":70},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT07038356","phase":"PHASE3","title":"Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"Christian Schulze","startDate":"2025-12-08","conditions":"Acute Decompensated Heart Failure (ADHF)","enrollment":536},{"nctId":"NCT05367063","phase":"PHASE4","title":"Canagliflozin and Myocardial Fibrosis","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-01-05","conditions":"Type 2 Diabetes, Cardiovascular Risk","enrollment":45},{"nctId":"NCT05672836","phase":"PHASE4","title":"ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement","status":"RECRUITING","sponsor":"Duk-Woo Park, MD","startDate":"2024-12-18","conditions":"Aortic Valve Stenosis, Heart Failure","enrollment":1040},{"nctId":"NCT06534411","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1023},{"nctId":"NCT07272057","phase":"NA","title":"SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-12-07","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07269197","phase":"","title":"Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes","status":"COMPLETED","sponsor":"Josip Juraj Strossmayer University of Osijek","startDate":"2024-03-22","conditions":"Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2","enrollment":67},{"nctId":"NCT05786443","phase":"PHASE2","title":"Safety and Efficacy of Empagliflozin in Hemodialysis","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-01-31","conditions":"End Stage Renal Disease","enrollment":60},{"nctId":"NCT05402579","phase":"","title":"Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2022-07-29","conditions":"Diabetes Type 2, DKA, Diabetic Ketoacidosis","enrollment":63},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT06828731","phase":"PHASE1","title":"Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes","status":"COMPLETED","sponsor":"Charles George VA Medical Center","startDate":"2024-12-06","conditions":"Prediabetes","enrollment":60},{"nctId":"NCT05390892","phase":"PHASE4","title":"PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-09-26","conditions":"Type2Diabetes, ASCVD","enrollment":6000},{"nctId":"NCT07241702","phase":"","title":"EFFECT OF HYBRID CLOSED-LOOP SYSTEMS ON CARDIOVASCULAR MARKERS IN TYPE 1 DIABETES.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attikon Hospital","startDate":"2019-09-01","conditions":"Type 1 Diabetes","enrollment":100},{"nctId":"NCT04633005","phase":"PHASE2","title":"Polypill Strategy for Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-11-15","conditions":"Heart Failure","enrollment":212},{"nctId":"NCT07240844","phase":"PHASE4","title":"Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy","status":"NOT_YET_RECRUITING","sponsor":"Seoul St. Mary's Hospital","startDate":"2025-11-24","conditions":"Amyloid Cardiomyopathy","enrollment":68},{"nctId":"NCT05989503","phase":"PHASE4","title":"Initiation of ARNi and SGLT2i in Patients With HFrEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2023-08-04","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":62},{"nctId":"NCT04447911","phase":"PHASE4","title":"Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-02-04","conditions":"Hyponatremia, SIADH, Liver Failure","enrollment":172},{"nctId":"NCT06446531","phase":"PHASE1","title":"Prevention of Progression of Prediabetes, Obesity and CV Risk","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-09-11","conditions":"Pre-Diabetes, Weight, Body, Cardiovascular Diseases","enrollment":64},{"nctId":"NCT07056699","phase":"PHASE3","title":"SGLT2i, Pioglitazone, and Ketone Production in T1D","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-01-30","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT07225465","phase":"PHASE2","title":"Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin","status":"NOT_YET_RECRUITING","sponsor":"St Vincent's Hospital Melbourne","startDate":"2026-02","conditions":"Type 1 Diabetes Mellitus","enrollment":115},{"nctId":"NCT06109311","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-11-10","conditions":"Type 2 Diabetes","enrollment":546},{"nctId":"NCT06843902","phase":"PHASE2","title":"Improving Coronary Vascular Health in Women","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-04-17","conditions":"HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease","enrollment":80},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT07204743","phase":"NA","title":"Efficacy and Safety of Dapagliflozin in Children With Proteinuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Quds University","startDate":"2025-08-15","conditions":"SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases","enrollment":10},{"nctId":"NCT07198191","phase":"","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2014-09-01","conditions":"Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)","enrollment":200000},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT07186153","phase":"","title":"Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-10-01","conditions":"SGLT 2 Inhibitors","enrollment":100},{"nctId":"NCT05330221","phase":"NA","title":"Project 2: ACHIEVE- HF","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2023-01-18","conditions":"Heart Failure, Hypertension","enrollment":364},{"nctId":"NCT07127406","phase":"","title":"Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kocaeli City Hospital","startDate":"2025-05-01","conditions":"Diabetic Ketoacidosis, Postoperative Care","enrollment":300},{"nctId":"NCT05468203","phase":"PHASE3","title":"PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-11-29","conditions":"Acute Kidney Injury","enrollment":3000},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT07169981","phase":"PHASE2","title":"Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-07-12","conditions":"Diabete Mellitus, Heart Failure, Remodeling, Left Ventricle","enrollment":200},{"nctId":"NCT06435858","phase":"PHASE2","title":"Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease","status":"RECRUITING","sponsor":"Cantonal Hospital Graubuenden","startDate":"2024-09-01","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1957,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SGLT2 inhibitors","dapagliflozin","canagliflozin","empagliflozin"],"phase":"marketed","status":"active","brandName":"Sodium-glucose cotransporter 2 inhibitor","genericName":"Sodium-glucose cotransporter 2 inhibitor","companyName":"Queen's University, Belfast","companyId":"queen-s-university-belfast","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SGLT2 inhibitors block the sodium-glucose cotransporter 2 in the kidney, preventing reabsorption of glucose and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}